Pamela Stringer
Family · Panama City, FLNPI 1114624038
Payments from drug & device makers
Across 146 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$522
- Merck$420
- Novartis$386
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$369
- Pfizer$179
- AstraZeneca$169
- plus $606 from 14 others
What the payments were for
- Food & beverage$2,652100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 36 | $522 |
| Merck | 19 | $420 |
| Novartis | 33 | $386 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $369 |
| Pfizer | 8 | $179 |
| AstraZeneca | 10 | $169 |
| Johnson & Johnson | 8 | $145 |
| Boehringer Ingelheim | 4 | $93 |
| Amgen | 5 | $74 |
| Scpharmaceuticals Inc. | 3 | $63 |
| Lexicon Pharmaceuticals, Inc. | 2 | $50 |
| Cvrx, Inc. | 2 | $29 |
| Boston Scientific | 2 | $26 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Bayer | 1 | $19 |
| GSK | 1 | $18 |
| Novo Nordisk | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Bridgebio Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$122
How this compares
$2,652 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 57 | $62,964 |
| EntrestoSacubitril/Valsartan | 19 | $26,914 |
| XareltoRivaroxaban | 22 | $17,379 |
| JardianceEmpagliflozin | 11 | $10,064 |
| Ranolazine ErRanolazine | 14 | $1,501 |
| Carvedilol | 110 | $1,159 |
| Metoprolol Succinate | 67 | $1,018 |
| Ezetimibe | 20 | $664 |
| Losartan Potassium | 50 | $527 |
| Digoxin | 17 | $448 |
| ClopidogrelClopidogrel Bisulfate | 32 | $445 |
| Rosuvastatin Calcium | 38 | $339 |
| Spironolactone | 61 | $312 |
| Atorvastatin Calcium | 28 | $288 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 15 | $248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $179 | $62,96457 claims |
| NovartisEntresto | $386 | $26,91419 claims |
| Johnson & JohnsonXarelto | $145 | $17,37922 claims |
| Boehringer IngelheimJardiance | $93 | $10,06411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Panama City
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.